MedTech Resources

Company

Cresilon

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.

Private

Total raised (reported)

$158M

8 Form D offerings, 2017 to 2026

Equity

$112M

Stock sold for cash

Debt and convertible notes

$29.0M

$29.0M of it convertible

Last known valuation

Unknown

Form D filings do not report valuation

Latest round: convertible note, $29.0M raised of $29.0M sought, first sale Apr 24, 2026, 217 investors. $17.2M was in other or unstated securities.

Funding rounds (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Apr 24, 2026Convertible note$29.0M$29.0M217Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $3.4MForm D/A ↗Jun 26, 20261 amendment
Nov 21, 2025Equity$6.7M$6.7M55Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $869KForm D ↗Dec 8, 2025
Apr 11, 2025Options or warrants$17.2M$34.8M95Rule 506(b)Agent: Paulson Investment Company, LLCCommissions $2.2MForm D ↗Sep 5, 2025
Apr 18, 2024Equity$25.0M$25.0M237Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $3.1MForm D ↗Jan 31, 2025
Aug 3, 2023Equity$17.2M$38.0M309Rule 506(b)Agent: Paulson Investment Company, LLCCommissions $2.2MForm D ↗Oct 8, 2024
Dec 17, 2021Equity$25.0M$25.0M308Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $3.2MForm D ↗Oct 18, 2022
Jan 29, 2021Equity$24.5M$45.3M170Rule 506(b)Agent: Paulson Investment Company, LLCCommissions $2.8MForm D ↗Feb 16, 2021
Dec 29, 2017Equity$13.3M$19.3M55Rule 506(b)Form D ↗Jan 12, 2018

Company details

From the company's latest Form D.

Legal name
Cresilon, Inc.
Headquarters
Brooklyn, New York
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Biotechnology

Executives, directors and promoters

As listed on the latest Form D.

  • Joseph LandolinaExecutive Officer, Director
  • Isaac MillerDirector
  • Scott LevineExecutive Officer

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

No 5%+ shareholder filings or SBIR grants found under the name Cresilon.

Latest FDA decisions

Search the Clearance Tracker

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar

No device trials list this company as lead sponsor.

Reports received

0

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

0

Injury reports

0

Death reports

0

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor

No reports to chart for this view.

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

No device types to rank.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

No brand names to rank.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recalls under this name in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.